Literature DB >> 25542550

Differences in Performance Status Assessment Among Palliative Care Specialists, Nurses, and Medical Oncologists.

Yu Jung Kim1, David Hui2, Yi Zhang3, Ji Chan Park4, Gary Chisholm5, Janet Williams2, Eduardo Bruera6.   

Abstract

CONTEXT: The Eastern Cooperative Oncology Group performance status (ECOG PS) is one of the most commonly used assessments in oncology and palliative care (PC). However, the interobserver differences between medical oncologists and PC specialists have never been reported.
OBJECTIVES: To determine the interobserver differences in ECOG PS assessment among PC specialists, PC nurses, and medical oncologists in patients with advanced cancer.
METHODS: We retrospectively reviewed the medical records of all patients who had an outpatient PC consultation in 2013 and identified 278 eligible patients. We retrieved the ECOG PS scores and symptom burden assessed by the Edmonton Symptom Assessment System (ESAS).
RESULTS: PC specialists (median +0.5, P < 0.0001) and nurses (median +1.0, P < 0.0001) rated the ECOG PS significantly higher than medical oncologists. The weighted kappa values were 0.26 between PC specialists and medical oncologists and 0.61 between PC specialists and nurses. PC specialists' assessments correlated with ESAS fatigue, dyspnea, anorexia, feeling of well-being, and symptom distress score. The ECOG PS assessments by all three groups were significantly associated with survival (P < 0.001). However, patients with ECOG PS 2 and 3-4 rated by their medical oncologists had similar survival (P = 0.67). Predictors of discordance in ECOG PS assessments between PC specialists and medical oncologists were the presence of a potentially effective treatment (odds ratio [OR] 2.39; 95% CI 1.09-5.23) and poor feeling of well-being (≥4) (OR 2.38, 95% CI 1.34-4.21).
CONCLUSION: ECOG PS assessments by PC specialists and nurses were significantly higher than those of medical oncologists. Systematic efforts to increase regular interdisciplinary communications may help to bridge this gap.
Copyright © 2015 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ECOG performance status; advanced cancer; medical oncologist; nurse; palliative care specialist

Mesh:

Year:  2014        PMID: 25542550     DOI: 10.1016/j.jpainsymman.2014.10.015

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  5 in total

1.  Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.

Authors:  Christoph Minichsdorfer; Andreas Gleiss; Marie-Bernadette Aretin; Manuela Schmidinger; Thorsten Fuereder
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

2.  Association of Early Palliative Care With Chemotherapy Intensity in Patients With Advanced Stage Lung Cancer: A National Cohort Study.

Authors:  Austin Lammers; Christopher G Slatore; Erik K Fromme; Kelly C Vranas; Donald R Sullivan
Journal:  J Thorac Oncol       Date:  2018-10-15       Impact factor: 15.609

3.  Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient.

Authors:  Anne Katrin Berger; Georg Martin Haag; Martin Ehmann; Anne Byl; Dirk Jäger; Christoph Springfeld
Journal:  BMC Gastroenterol       Date:  2017-12-06       Impact factor: 3.067

4.  Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals.

Authors:  Faisal Azam; Muhammad Farooq Latif; Ayesha Farooq; Syed Hammad Tirmazy; Saad AlShahrani; Shahid Bashir; Nedal Bukhari
Journal:  Case Rep Oncol       Date:  2019-09-25

Review 5.  Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review.

Authors:  David Hui; Yee-Choon Meng; Sebastian Bruera; Yimin Geng; Ron Hutchins; Masanori Mori; Florian Strasser; Eduardo Bruera
Journal:  Oncologist       Date:  2016-05-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.